Please assess the completion status of the following clinical trial:

Trial Title: A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must agree to undergo tumor HRD testing and blood gBRCAmut status testing.~* Patients of childbearing potential must have negative pregnancy serum test within 72 hours of being dosed~* Patients must have histologically diagnosed high-grade (Grade 2 or 3) serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent disease and must have been previously treated with chemotherapy and experienced a response lasting at least 6 months to first-line platinum based therapy.~* Patients Must have completed 3 or 4 previous chemotherapy regimens.~* Patients must have completed their last chemotherapy regimen \> 4 weeks prior to treatment initiation.~* Patients must have measurable disease according to RECIST (v.1.1).~* Patients must have formalin-fixed, paraffin-embedded tumor samples available from the primary or recurrent cancer or agree to undergo fresh biopsy prior to study treatment initiation.~* Patients must agree to blood samples during screening and at the end of treatment for cytogenetic analysis.~Exclusion Criteria:~* Patients must not have any known, persistent (\> 4 weeks), ≥Grade 3 hematologic toxicity during the last cancer therapy. Patients must not have any known, persistent (\>4 weeks), ≥ Grade 3 fatigue during the last cancer therapy.~* Patients must not have received pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment.~* Patients must not have symptomatic uncontrolled brain or leptomeningeal metastases.~* Patients must not be considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active, uncontrolled infection.~* Patients must not have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment.~* Patients must not have known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Niraparib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).